UA125204C2 - Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях - Google Patents
Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях Download PDFInfo
- Publication number
- UA125204C2 UA125204C2 UAA201603367A UAA201603367A UA125204C2 UA 125204 C2 UA125204 C2 UA 125204C2 UA A201603367 A UAA201603367 A UA A201603367A UA A201603367 A UAA201603367 A UA A201603367A UA 125204 C2 UA125204 C2 UA 125204C2
- Authority
- UA
- Ukraine
- Prior art keywords
- free
- disease
- antibody
- sequence
- primarily
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 61
- 102000004169 proteins and genes Human genes 0.000 title claims description 46
- 208000027866 inflammatory disease Diseases 0.000 title description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 457
- 201000010099 disease Diseases 0.000 claims abstract description 275
- 208000035475 disorder Diseases 0.000 claims abstract description 181
- 238000011282 treatment Methods 0.000 claims abstract description 158
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 104
- 238000000034 method Methods 0.000 claims abstract description 102
- 239000012634 fragment Substances 0.000 claims abstract description 96
- 238000001514 detection method Methods 0.000 claims abstract description 54
- 230000009870 specific binding Effects 0.000 claims abstract description 34
- 230000002159 abnormal effect Effects 0.000 claims abstract description 32
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 24
- 210000001124 body fluid Anatomy 0.000 claims abstract description 17
- 239000010839 body fluid Substances 0.000 claims abstract description 17
- 230000027455 binding Effects 0.000 claims description 141
- 239000000203 mixture Substances 0.000 claims description 61
- 241000282414 Homo sapiens Species 0.000 claims description 59
- 210000002966 serum Anatomy 0.000 claims description 55
- 210000001519 tissue Anatomy 0.000 claims description 54
- 210000004072 lung Anatomy 0.000 claims description 53
- 239000003937 drug carrier Substances 0.000 claims description 41
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 40
- 238000011161 development Methods 0.000 claims description 35
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 28
- 230000001965 increasing effect Effects 0.000 claims description 28
- 239000012530 fluid Substances 0.000 claims description 27
- 230000004054 inflammatory process Effects 0.000 claims description 27
- 206010061218 Inflammation Diseases 0.000 claims description 26
- 241000699670 Mus sp. Species 0.000 claims description 26
- 238000012545 processing Methods 0.000 claims description 22
- 238000007634 remodeling Methods 0.000 claims description 22
- 206010036790 Productive cough Diseases 0.000 claims description 19
- 230000001575 pathological effect Effects 0.000 claims description 19
- 210000001147 pulmonary artery Anatomy 0.000 claims description 19
- 210000003802 sputum Anatomy 0.000 claims description 18
- 208000024794 sputum Diseases 0.000 claims description 18
- 206010014561 Emphysema Diseases 0.000 claims description 17
- 208000007660 Residual Neoplasm Diseases 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 230000007423 decrease Effects 0.000 claims description 16
- 230000006870 function Effects 0.000 claims description 16
- 230000035945 sensitivity Effects 0.000 claims description 16
- 230000009885 systemic effect Effects 0.000 claims description 16
- 238000002054 transplantation Methods 0.000 claims description 16
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 15
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 15
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 14
- 206010013774 Dry eye Diseases 0.000 claims description 14
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 14
- 208000011580 syndromic disease Diseases 0.000 claims description 14
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 13
- 230000006378 damage Effects 0.000 claims description 13
- 238000012544 monitoring process Methods 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 210000000440 neutrophil Anatomy 0.000 claims description 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
- 108091008324 binding proteins Proteins 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 11
- 206010019280 Heart failures Diseases 0.000 claims description 10
- 206010054949 Metaplasia Diseases 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
- 230000004199 lung function Effects 0.000 claims description 10
- 230000015689 metaplastic ossification Effects 0.000 claims description 10
- 230000001413 cellular effect Effects 0.000 claims description 9
- 239000000945 filler Substances 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 206010010741 Conjunctivitis Diseases 0.000 claims description 8
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 8
- 208000011231 Crohn disease Diseases 0.000 claims description 8
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 8
- 102000016942 Elastin Human genes 0.000 claims description 8
- 108010014258 Elastin Proteins 0.000 claims description 8
- 208000004930 Fatty Liver Diseases 0.000 claims description 8
- 208000010412 Glaucoma Diseases 0.000 claims description 8
- 201000005569 Gout Diseases 0.000 claims description 8
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 8
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 8
- 208000004852 Lung Injury Diseases 0.000 claims description 8
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 8
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims description 8
- 206010029113 Neovascularisation Diseases 0.000 claims description 8
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 8
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims description 8
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 8
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 201000004982 autoimmune uveitis Diseases 0.000 claims description 8
- 201000009267 bronchiectasis Diseases 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 201000000159 corneal neovascularization Diseases 0.000 claims description 8
- 230000008021 deposition Effects 0.000 claims description 8
- 230000008034 disappearance Effects 0.000 claims description 8
- 229920002549 elastin Polymers 0.000 claims description 8
- 210000000744 eyelid Anatomy 0.000 claims description 8
- 230000002489 hematologic effect Effects 0.000 claims description 8
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 8
- 201000004614 iritis Diseases 0.000 claims description 8
- 206010023332 keratitis Diseases 0.000 claims description 8
- 231100000515 lung injury Toxicity 0.000 claims description 8
- 208000002780 macular degeneration Diseases 0.000 claims description 8
- 208000025487 periodic fever syndrome Diseases 0.000 claims description 8
- 238000002271 resection Methods 0.000 claims description 8
- 230000028327 secretion Effects 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 8
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 7
- 208000009137 Behcet syndrome Diseases 0.000 claims description 7
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 7
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims description 7
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 7
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- 230000009385 viral infection Effects 0.000 claims description 7
- 206010010984 Corneal abrasion Diseases 0.000 claims description 6
- 208000028006 Corneal injury Diseases 0.000 claims description 6
- 208000034327 Tumor necrosis factor receptor 1 associated periodic syndrome Diseases 0.000 claims description 6
- 208000032594 Vascular Remodeling Diseases 0.000 claims description 6
- 201000003308 autosomal dominant familial periodic fever Diseases 0.000 claims description 6
- 210000000941 bile Anatomy 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 6
- 210000001732 sebaceous gland Anatomy 0.000 claims description 6
- 210000004243 sweat Anatomy 0.000 claims description 6
- 210000001138 tear Anatomy 0.000 claims description 6
- 206010063837 Reperfusion injury Diseases 0.000 claims description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 5
- 238000005299 abrasion Methods 0.000 claims description 5
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 5
- 201000007717 corneal ulcer Diseases 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 230000004528 endothelial cell apoptotic process Effects 0.000 claims description 5
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 4
- 208000006029 Cardiomegaly Diseases 0.000 claims description 4
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 230000000762 glandular Effects 0.000 claims description 4
- 230000003248 secreting effect Effects 0.000 claims description 4
- 230000018528 secretion by tissue Effects 0.000 claims description 4
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims 4
- 235000014101 wine Nutrition 0.000 claims 2
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 claims 1
- 241000167854 Bourreria succulenta Species 0.000 claims 1
- 101100400991 Caenorhabditis elegans mek-1 gene Proteins 0.000 claims 1
- 244000068645 Carya illinoensis Species 0.000 claims 1
- 235000009025 Carya illinoensis Nutrition 0.000 claims 1
- 244000157795 Cordia myxa Species 0.000 claims 1
- 235000004257 Cordia myxa Nutrition 0.000 claims 1
- 244000241257 Cucumis melo Species 0.000 claims 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 241001575049 Sonia Species 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims 1
- 235000019693 cherries Nutrition 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000000446 fuel Substances 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 230000009325 pulmonary function Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 abstract description 285
- 102000003810 Interleukin-18 Human genes 0.000 abstract description 282
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 abstract description 3
- 102000043959 human IL18 Human genes 0.000 abstract description 3
- 102000044166 interleukin-18 binding protein Human genes 0.000 abstract description 3
- 108010070145 interleukin-18 binding protein Proteins 0.000 abstract description 3
- 102100035017 Interleukin-18-binding protein Human genes 0.000 abstract 5
- 101710205006 Interleukin-18-binding protein Proteins 0.000 abstract 5
- 239000003112 inhibitor Substances 0.000 description 155
- 239000000523 sample Substances 0.000 description 76
- 230000014509 gene expression Effects 0.000 description 68
- 239000000779 smoke Substances 0.000 description 65
- 230000003042 antagnostic effect Effects 0.000 description 63
- 239000013604 expression vector Substances 0.000 description 45
- 239000000427 antigen Substances 0.000 description 44
- 102000036639 antigens Human genes 0.000 description 44
- 108091007433 antigens Proteins 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 43
- 241000208125 Nicotiana Species 0.000 description 41
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 41
- 210000000476 body water Anatomy 0.000 description 37
- 230000000694 effects Effects 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 33
- 108060003951 Immunoglobulin Proteins 0.000 description 26
- 230000005713 exacerbation Effects 0.000 description 26
- 102000018358 immunoglobulin Human genes 0.000 description 26
- 239000000843 powder Substances 0.000 description 26
- 102000004127 Cytokines Human genes 0.000 description 25
- 108090000695 Cytokines Proteins 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 239000003814 drug Substances 0.000 description 24
- 230000005764 inhibitory process Effects 0.000 description 20
- 108700023707 TUG1 Proteins 0.000 description 19
- 230000001105 regulatory effect Effects 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 150000001875 compounds Chemical class 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- 102000037865 fusion proteins Human genes 0.000 description 17
- 108020001507 fusion proteins Proteins 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 239000013543 active substance Substances 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 16
- 230000001900 immune effect Effects 0.000 description 16
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 101150060303 SOK2 gene Proteins 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 230000000770 proinflammatory effect Effects 0.000 description 14
- 210000002345 respiratory system Anatomy 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 13
- 239000000090 biomarker Substances 0.000 description 13
- 229960003957 dexamethasone Drugs 0.000 description 13
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 13
- 230000006698 induction Effects 0.000 description 13
- 230000008595 infiltration Effects 0.000 description 13
- 238000001764 infiltration Methods 0.000 description 13
- 210000004400 mucous membrane Anatomy 0.000 description 13
- 230000002685 pulmonary effect Effects 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 13
- 238000013459 approach Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 208000019622 heart disease Diseases 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 230000000391 smoking effect Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000004448 titration Methods 0.000 description 11
- 102000001708 Protein Isoforms Human genes 0.000 description 10
- 108010029485 Protein Isoforms Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 238000010172 mouse model Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 125000004122 cyclic group Chemical group 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- -1 glidants Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 230000009102 absorption Effects 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000009260 cross reactivity Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 238000011144 upstream manufacturing Methods 0.000 description 8
- 102000014914 Carrier Proteins Human genes 0.000 description 7
- 102000000589 Interleukin-1 Human genes 0.000 description 7
- 108010002352 Interleukin-1 Proteins 0.000 description 7
- 101100149884 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SOV1 gene Proteins 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000000692 anti-sense effect Effects 0.000 description 7
- 239000013060 biological fluid Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000004364 calculation method Methods 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 235000019504 cigarettes Nutrition 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000004005 microsphere Substances 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000001132 alveolar macrophage Anatomy 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 230000008054 signal transmission Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 210000001635 urinary tract Anatomy 0.000 description 6
- 230000003313 weakening effect Effects 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 230000001387 anti-histamine Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000000739 antihistaminic agent Substances 0.000 description 5
- 229940088623 biologically active substance Drugs 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 229940124630 bronchodilator Drugs 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 229940126601 medicinal product Drugs 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 230000008707 rearrangement Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102100031910 A-kinase anchor protein 3 Human genes 0.000 description 4
- 206010006458 Bronchitis chronic Diseases 0.000 description 4
- 101100203924 Caenorhabditis elegans sorb-1 gene Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000774732 Homo sapiens A-kinase anchor protein 3 Proteins 0.000 description 4
- 101000703761 Homo sapiens Leucine-rich repeat protein SHOC-2 Proteins 0.000 description 4
- 206010020880 Hypertrophy Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000005862 Whey Substances 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004712 air sac Anatomy 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000000954 anitussive effect Effects 0.000 description 4
- 229940124584 antitussives Drugs 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000007451 chronic bronchitis Diseases 0.000 description 4
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 4
- 208000037765 diseases and disorders Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 4
- 230000001323 posttranslational effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 210000001179 synovial fluid Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108090000426 Caspase-1 Proteins 0.000 description 3
- 102100035904 Caspase-1 Human genes 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000001066 destructive effect Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000009750 upstream signaling Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100367084 Caenorhabditis elegans such-1 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000628693 Homo sapiens Serine/threonine-protein kinase 25 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229940117027 Long-acting beta 2 adrenoceptor (LABA) agonist Drugs 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 101100491259 Oryza sativa subsp. japonica AP2-2 gene Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100026737 Serine/threonine-protein kinase 25 Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 2
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 2
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000003915 air pollution Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000012226 gene silencing method Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000011475 lollipops Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- AXOXZJJMUVSZQY-BVDKBYOBSA-N sip 20 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(C)O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)O)C(C)O)C1=CC=CC=C1 AXOXZJJMUVSZQY-BVDKBYOBSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- 150000000093 1,3-dioxanes Chemical class 0.000 description 1
- 125000006091 1,3-dioxolane group Chemical class 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 201000010053 Alcoholic Cardiomyopathy Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 206010057454 Aortic valve prolapse Diseases 0.000 description 1
- 101100322820 Arabidopsis thaliana AHL29 gene Proteins 0.000 description 1
- 101100123324 Arabidopsis thaliana RAT5 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940124697 COPD therapeutics Drugs 0.000 description 1
- 101100401100 Caenorhabditis elegans mes-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000193610 Canis rufus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007637 Cardiomyopathy alcoholic Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101100492693 Danio rerio atp5if1a gene Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229940090898 Desensitizer Drugs 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical class CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- 101150022794 IDS2 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101100203593 Marchantia polymorpha SOK gene Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003430 Mitral Valve Prolapse Diseases 0.000 description 1
- 206010027727 Mitral valve incompetence Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100456571 Mus musculus Med12 gene Proteins 0.000 description 1
- 101100310622 Mus musculus Soga1 gene Proteins 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical class CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 241000282330 Procyon lotor Species 0.000 description 1
- 101000720907 Pseudomonas savastanoi pv. phaseolicola Ornithine carbamoyltransferase 1, anabolic Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- RVKFQAJIXCZXQY-CBZIJGRNSA-N [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] sulfamate Chemical compound NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 RVKFQAJIXCZXQY-CBZIJGRNSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- MSRLEKWLCBQBDR-UHFFFAOYSA-N azepan-2-one;tetradecanoic acid Chemical compound O=C1CCCCCN1.CCCCCCCCCCCCCC(O)=O MSRLEKWLCBQBDR-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CNYFJCCVJNARLE-UHFFFAOYSA-L calcium;2-sulfanylacetic acid;2-sulfidoacetate Chemical compound [Ca+2].[O-]C(=O)CS.[O-]C(=O)CS CNYFJCCVJNARLE-UHFFFAOYSA-L 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical group O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000004955 epithelial membrane Anatomy 0.000 description 1
- 101150001429 esf1 gene Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 206010049430 peripartum cardiomyopathy Diseases 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 208000009138 pulmonary valve stenosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 101150114085 soc-2 gene Proteins 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000003270 subclavian artery Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- 238000010153 Šidák test Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Zoology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13183193 | 2013-09-05 | ||
| PCT/EP2014/069013 WO2015032932A1 (en) | 2013-09-05 | 2014-09-05 | Il-18 binding protein (il-18bp) in inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA125204C2 true UA125204C2 (uk) | 2022-02-02 |
Family
ID=49111035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201603367A UA125204C2 (uk) | 2013-09-05 | 2014-09-05 | Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10858426B2 (enExample) |
| EP (2) | EP3041864B1 (enExample) |
| JP (2) | JP6820743B2 (enExample) |
| KR (2) | KR102512797B1 (enExample) |
| CN (2) | CN105722858A (enExample) |
| AU (1) | AU2014317035B2 (enExample) |
| CA (1) | CA2922498A1 (enExample) |
| CL (1) | CL2016000506A1 (enExample) |
| CY (1) | CY1124698T1 (enExample) |
| DK (1) | DK3041864T3 (enExample) |
| ES (1) | ES2892923T3 (enExample) |
| HU (1) | HUE055608T2 (enExample) |
| IL (1) | IL244169B (enExample) |
| LT (1) | LT3041864T (enExample) |
| MX (1) | MX385868B (enExample) |
| NZ (1) | NZ717671A (enExample) |
| PH (1) | PH12016500425B1 (enExample) |
| PL (1) | PL3041864T3 (enExample) |
| PT (1) | PT3041864T (enExample) |
| RU (1) | RU2731713C2 (enExample) |
| SG (1) | SG11201601717VA (enExample) |
| SI (1) | SI3041864T1 (enExample) |
| UA (1) | UA125204C2 (enExample) |
| WO (1) | WO2015032932A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2892923T3 (es) | 2013-09-05 | 2022-02-07 | Ab2 Bio Sa | Proteína de unión a IL-18 (IL-18BP) en enfermedades inflamatorias |
| EP3265807A1 (en) | 2015-03-05 | 2018-01-10 | AB2 Bio SA | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases |
| US20180362660A1 (en) * | 2016-05-09 | 2018-12-20 | Schickwann Tsai | Anti-penumbra monoclonal antibodies for detection and therapy of normal and abnormal B lymphocytes |
| GB201614455D0 (en) * | 2016-08-24 | 2016-10-05 | Univ Oxford Innovation Ltd | Biomarkers |
| DE102016219607B4 (de) * | 2016-10-10 | 2025-04-30 | Siemens Healthineers Ag | Erzeugung einer mit anatomischen Bilddaten korrelierten Ergebniskarte |
| US11629183B2 (en) | 2017-12-29 | 2023-04-18 | University Of Florida Research Foundation, Inc. | Monoclonal antibodies targeting microtubule-binding domain of tau protein and methods of detecting tau protein in vivo |
| TWI679279B (zh) * | 2018-05-09 | 2019-12-11 | 臺中榮民總醫院 | 檢測成人發作型史笛兒氏症之罹病風險及預後之方法 |
| AU2019290099B2 (en) | 2018-06-19 | 2025-12-11 | Shanghaitech University | Human antibodies to human interleukin 18 receptor alpha and beta |
| EP3892300A4 (en) * | 2018-12-03 | 2022-12-14 | Mabprotein Co.,Ltd. | ANTIBODIES RECOGNIZING A NEO-EPITOPE OF ACTIVATED INTERLEUKIN-18 PROTEINS AND ASSOCIATED APPLICATION |
| CN110433289B (zh) * | 2019-09-10 | 2024-12-17 | 中山大学附属口腔医院 | 用于治疗牙周致病菌感染引起的牙周膜细胞功能紊乱与牙槽骨丧失的药物 |
| CA3158323A1 (en) * | 2019-11-04 | 2021-05-14 | Medimmune Limited | Methods of using il-33 antagonists |
| EP4146174A1 (en) * | 2020-05-06 | 2023-03-15 | AB2 Bio SA | Il-18 binding protein (il-18bp) in respiratory diseases |
| GB202007404D0 (en) * | 2020-05-19 | 2020-07-01 | Nasser Syed Muhammad Tahir | Treatment for viral respiratory infections |
| US20230242623A1 (en) * | 2020-07-08 | 2023-08-03 | Georgia Tech Research Corporation | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection |
| EP3943097A1 (en) | 2020-07-24 | 2022-01-26 | AB2 Bio SA | Car-t cell therapy |
| KR20220044057A (ko) * | 2020-09-29 | 2022-04-06 | 주식회사 에이프릴바이오 | 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도 |
| JP2023549257A (ja) | 2020-11-18 | 2023-11-22 | ノバルティス アーゲー | Ｎｌｒｃ４－ｇｏｆインフラマソーム病の処置における使用のための二特異性抗体 |
| EP4371573A4 (en) | 2021-07-13 | 2025-08-20 | National Univ Corporation Tokai National Higher Education And Research System | MEDICINAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE |
| WO2023067348A1 (en) * | 2021-10-21 | 2023-04-27 | Biosirius Ltd | Treatment for virally-induced pneumonia |
| CN114236139A (zh) * | 2021-12-30 | 2022-03-25 | 苏州和锐生物科技有限公司 | 一种TNF-α生物制剂的抗体检测试剂盒、制备方法 |
| US20250179131A1 (en) | 2022-03-04 | 2025-06-05 | Ab2 Bio Sa | Il-18 binding protein (il-18bp) in the treatment of vexas |
| WO2024148232A2 (en) | 2023-01-06 | 2024-07-11 | Alector Llc | Anti-il18 binding protein antibodies and methods of use thereof |
| AU2024206448A1 (en) | 2023-01-06 | 2025-08-21 | Lassen Therapeutics, Inc. | Anti-il-18bp antibodies |
| TW202434634A (zh) * | 2023-02-20 | 2024-09-01 | 大陸商瑞石生物醫藥有限公司 | 抗IL-18Rβ抗體、其抗原結合片段及其醫藥應用 |
| AU2024238511A1 (en) * | 2023-03-21 | 2025-10-02 | Coya Therapeutics, Inc. | Biomarkers of amyotrophic lateral sclerosis and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| KR100234520B1 (ko) | 1991-01-18 | 1999-12-15 | 그레고리 아보트 | 종양괴사인자 매개병 치료용 의약품 조성물 |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| ES2176342T5 (es) | 1994-10-21 | 2010-02-09 | Innogenetics N.V. | Secuencias del genotipo 7 del virus de la hepatitis c y su utilizacion como agentes profilacticos, terapeuticos y de diagnosticos. |
| US5756662A (en) | 1995-03-14 | 1998-05-26 | Corixa Corporation | Compounds and methods for the detection of T. cruzi infection |
| US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
| IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
| EP2338515A3 (en) | 2000-02-10 | 2011-11-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
| RS51737B (sr) * | 2000-02-21 | 2011-10-31 | Laboratoires Serono Sa. | Korišćenje inhibitora il-18 |
| SI1278540T1 (sl) | 2000-05-05 | 2008-10-31 | Edicale Inserm Inst Nat De La | Uporaba inhibitorjev il-18 za zdravljenje in/ali preventivo ateroskleroze |
| US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
| MXPA03001915A (es) | 2000-08-03 | 2004-09-10 | Therapeutic Human Polyclonals | Produccion de anticuerpos humanizados en animales transgenicos. |
| AU2002224417A1 (en) | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
| RS51125B (sr) * | 2001-01-29 | 2010-10-31 | Laboratoires Serono Sa. | Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja |
| ES2334773T3 (es) * | 2001-05-16 | 2010-03-16 | Yeda Research And Development Co. Ltd. | Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis. |
| CN1305529C (zh) | 2001-05-25 | 2007-03-21 | 阿雷斯贸易股份有限公司 | Il－18抑制剂在治疗或预防中枢神经系统损伤中的应用 |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| EP1622939B1 (en) * | 2003-05-13 | 2012-03-14 | Merck Serono SA | Active variants of the il-18 binding protein and medical uses thereof |
| US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
| AU2011224023C1 (en) | 2003-11-12 | 2013-08-29 | Abbvie Inc. | IL-18 binding proteins |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| WO2005087249A1 (ja) | 2004-03-11 | 2005-09-22 | Kurume University | プロテアーゼ阻害剤及び疾患の予防又は治療剤 |
| EP1773403B1 (en) | 2004-07-09 | 2018-04-25 | The University of North Carolina At Chapel Hill | Alphavirus-based adjuvants |
| NZ552837A (en) | 2004-08-20 | 2009-09-25 | Smithkline Beecham Corp | Use of human IL-18 polypeptide for treating mucositis and diabetic ulcers |
| JP5199073B2 (ja) | 2005-06-03 | 2013-05-15 | アレス トレーディング ソシエテ アノニム | 組換えｉｌ−１８結合タンパク質の生産 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7910318B2 (en) | 2005-09-15 | 2011-03-22 | The Royal Institution For The Advancement Of Learning/Mcgill University | Methods of diagnosing ovarian cancer and kits therefor |
| WO2008091588A1 (en) | 2007-01-22 | 2008-07-31 | Targacept, Inc. | Intranasal, buccal, and sublingual administration of metanicotine analogs |
| EP2164517A4 (en) | 2007-05-29 | 2011-03-09 | Univ Yale | INHIBITION OF IL-18 AND PROTEIN KINASE R IN THE TREATMENT OF OBSTRUCTIVE CHRONIC BRONCHOPNEUMOPATHY |
| JP2014508511A (ja) | 2010-12-20 | 2014-04-10 | メドイミューン・リミテッド | 抗ｉｌ−１８抗体およびそれらの使用 |
| JOP20200308A1 (ar) * | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
| ES2892923T3 (es) | 2013-09-05 | 2022-02-07 | Ab2 Bio Sa | Proteína de unión a IL-18 (IL-18BP) en enfermedades inflamatorias |
| EP3265807A1 (en) * | 2015-03-05 | 2018-01-10 | AB2 Bio SA | Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases |
-
2014
- 2014-09-05 ES ES14759210T patent/ES2892923T3/es active Active
- 2014-09-05 LT LTEPPCT/EP2014/069013T patent/LT3041864T/lt unknown
- 2014-09-05 RU RU2016112596A patent/RU2731713C2/ru active
- 2014-09-05 JP JP2016539564A patent/JP6820743B2/ja active Active
- 2014-09-05 CN CN201480060413.7A patent/CN105722858A/zh active Pending
- 2014-09-05 KR KR1020217034984A patent/KR102512797B1/ko active Active
- 2014-09-05 AU AU2014317035A patent/AU2014317035B2/en active Active
- 2014-09-05 DK DK14759210.9T patent/DK3041864T3/da active
- 2014-09-05 EP EP14759210.9A patent/EP3041864B1/en active Active
- 2014-09-05 PL PL14759210T patent/PL3041864T3/pl unknown
- 2014-09-05 WO PCT/EP2014/069013 patent/WO2015032932A1/en not_active Ceased
- 2014-09-05 EP EP21181013.0A patent/EP3978526A1/en active Pending
- 2014-09-05 CA CA2922498A patent/CA2922498A1/en active Pending
- 2014-09-05 PH PH1/2016/500425A patent/PH12016500425B1/en unknown
- 2014-09-05 CN CN202210945119.0A patent/CN115925928A/zh active Pending
- 2014-09-05 HU HUE14759210A patent/HUE055608T2/hu unknown
- 2014-09-05 SG SG11201601717VA patent/SG11201601717VA/en unknown
- 2014-09-05 MX MX2016002719A patent/MX385868B/es unknown
- 2014-09-05 KR KR1020167008846A patent/KR102321172B1/ko active Active
- 2014-09-05 NZ NZ717671A patent/NZ717671A/en unknown
- 2014-09-05 PT PT14759210T patent/PT3041864T/pt unknown
- 2014-09-05 SI SI201431879T patent/SI3041864T1/sl unknown
- 2014-09-05 UA UAA201603367A patent/UA125204C2/uk unknown
- 2014-09-05 US US14/916,917 patent/US10858426B2/en active Active
-
2016
- 2016-02-17 IL IL244169A patent/IL244169B/en active IP Right Grant
- 2016-03-04 CL CL2016000506A patent/CL2016000506A1/es unknown
-
2019
- 2019-11-21 JP JP2019210436A patent/JP2020055821A/ja active Pending
-
2020
- 2020-05-26 US US16/883,735 patent/US11530263B2/en active Active
-
2021
- 2021-09-16 CY CY20211100816T patent/CY1124698T1/el unknown
-
2022
- 2022-11-14 US US18/054,936 patent/US20230250164A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA125204C2 (uk) | Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях | |
| UA128752C2 (uk) | Фармацевтична композиція для лікування асоційованого з il-18 захворювання або порушення | |
| JP5118491B2 (ja) | ｔｏｌｌ様レセプターを標的とする併用療法およびその使用 | |
| JP2017160178A (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| US20250339428A1 (en) | Methods of treating sjogren's syndrome using a bruton's tyrosine kinase inhibitor | |
| WO2022049614A1 (ja) | Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物 | |
| JPWO2016167263A1 (ja) | Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物 | |
| Sung et al. | Ischemia‐induced cardiac dysfunction is exacerbated in adiponectin‐knockout mice due to impaired autophagy flux | |
| US10676522B2 (en) | Methods of selectively treating asthma using IL-17 antagonists | |
| Greinacher et al. | Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) | |
| BR112016004772B1 (pt) | Método para determinação da quantidade de il-18 livre em uma amostra ou in situ, uso de um inibidor de il-18, e, kit de diagnóstico para detectar il-18 livre | |
| Quillinan | Treatment of Diffuse Cutaneous Systemic Sclerosis with Hyperimmune Caprine Serum | |
| HK1221726B (en) | Il-18 binding protein (il-18bp) in inflammatory diseases | |
| CA2474590A1 (en) | Treatment of male sexual dysfunction |